New YorkUS edition · Updated hourlyLoading the wire
The intelligence brief for hedge funds, allocators and active investors

HedgeWeekly

Wall Street · Washington · The World
New York edition
Latest
Headlines appear here as the desk files
The first edition is being filed.The news desk publishes every hour. Stories appear as soon as the editor approves them.

Most recent

    Today's coverage

    US 0Global 0
    Rolling 24 hours · line marks the 60% US target

    HedgeWeekly Video

    The 60-second briefing · Weekdays before the bell
    Coming soonThe morning in sixty secondsThree stories moving US markets, filed before the open.
    Coming soonHedge fund positioningWhat the prime books are telling us this week.
    Coming soonEarnings, explainedThe numbers that mattered and what changed.
    SponsoredPresent this seriesTitle sponsorship of HedgeWeekly Video is open.

    Markets

    Stockwatch

    HedgeWeekly Stockwatch: Nvidia's test week, Baidu's AI cloud growth

    Nvidia heads into results, AMD slides, Baidu reports, Summit falls on an FDA rejection and Strategy tracks bitcoin.

    HedgeWeekly Markets Desk ·

    NVDA, Nvidia: Third-quarter results land Tuesday after the close, the first under interim CEO Colette Kress. The FT reported Jensen Huang and allies are discussing a campaign to bring him back. Bull case: Bloomberg consensus sees revenue near $109.1 billion, up about 91% on the year, Saxo said. Bear case: Shares fell nearly 13% last week; leadership remains unsettled before the report.

    AMD, Advanced Micro Devices: Early gains reversed in a sector-wide AI-chip sell-off on Friday, after the shares rose as much as 30% earlier in the week, The Motley Fool reported. Bull case: Data-centre sales nearly doubled year on year in the latest quarter. Bear case: Heavy volume, about double normal, suggests profit-taking after a sharp run.

    BIDU, Baidu: Third-quarter revenue was 30.81 billion yuan, just below the 30.86 billion estimate. AI cloud infrastructure revenue rose 94% to 8.2 billion yuan, Rallies.ai reported. Bull case: Adjusted EPS of $1.01 beat consensus by $0.09, GuruFocus said. Bear case: Total revenue missed slightly; the stock is down more than 40% this year.

    SMMT, Summit Therapeutics: The FDA rejected its application for ivonescimab in previously treated, EGFR-mutated lung cancer, Stocktwits reported. Bull case: The company can respond to the FDA and pursue other lung cancer uses. Bear case: The rejection delays the drug's US arrival in its lead indication.

    MSTR, Strategy: Bitcoin fell to about $61,946 overnight before steadying near $64,800. Spot bitcoin funds have seen seven straight days of outflows, about $1.91 billion. Bull case: Bitcoin bounced more than $2,800 from its overnight low, CryptoTicker data showed. Bear case: MSCI is removing Strategy from its indexes, and fund outflows continue.

    Sources

    The Archive